Impact of Next-generation Sequencing on Interobserver Agreement and Diagnosis of Spitzoid Neoplasms.
Journal
The American journal of surgical pathology
ISSN: 1532-0979
Titre abrégé: Am J Surg Pathol
Pays: United States
ID NLM: 7707904
Informations de publication
Date de publication:
01 12 2021
01 12 2021
Historique:
entrez:
10
11
2021
pubmed:
11
11
2021
medline:
30
11
2021
Statut:
ppublish
Résumé
Atypical Spitzoid melanocytic tumors are diagnostically challenging. Many studies have suggested various genomic markers to improve classification and prognostication. We aimed to assess whether next-generation sequencing studies using the Tempus xO assay assessing mutations in 1711 cancer-related genes and performing whole transcriptome mRNA sequencing for structural alterations could improve diagnostic agreement and accuracy in assessing neoplasms with Spitzoid histologic features. Twenty expert pathologists were asked to review 70 consultation level cases with Spitzoid features, once with limited clinical information and again with additional genomic information. There was an improvement in overall agreement with additional genomic information. Most significantly, there was increase in agreement of the diagnosis of conventional melanoma from moderate (κ=0.470, SE=0.0105) to substantial (κ=0.645, SE=0.0143) as measured by an average Cohen κ. Clinical follow-up was available in all 70 cases which substantiated that the improved agreement was clinically significant. Among 3 patients with distant metastatic disease, there was a highly significant increase in diagnostic recognition of the cases as conventional melanoma with genomics (P<0.005). In one case, none of 20 pathologists recognized a tumor with BRAF and TERT promoter mutations associated with fatal outcome as a conventional melanoma when only limited clinical information was provided, whereas 60% of pathologists correctly diagnosed this case when genomic information was also available. There was also a significant improvement in agreement of which lesions should be classified in the Spitz category/WHO Pathway from an average Cohen κ of 0.360 (SE=0.00921) to 0.607 (SE=0.0232) with genomics.
Identifiants
pubmed: 34757982
doi: 10.1097/PAS.0000000000001753
pii: 00000478-202112000-00003
doi:
Substances chimiques
Biomarkers, Tumor
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1597-1605Informations de copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of Interest and Source of Funding: This study was supported by the IDP Foundation Inc. R.A.S. is supported by a National Health and Medical Research Council of Australia (NHMRC) Program Grant and Practitioner Fellowship. P.G. has received royalties from Elsevier for textbooks and has served as a consultant for Castle Biosciences and DermTech Inc. K.B. has received royalties from Elsevier for textbooks. R.A.S. has received fees for professional services from Qbiotics, Novartis, Merck Sharp & Dohme, NeraCare, AMGEN Inc., Bristol-Myers Squibb, Myriad Genetics, and GlaxoSmithKline. C.R.S. has received fees for professional services from Myriad Genetics, Novartis, Orlucent, and SkinCure Oncology. M.T.T. has served as a consultant and advisor for Myriad Genetics, Merck Sharp & Dohme, Nanostring LLC, and Novartis. For the remaining authors none were declared.
Références
Lee JJ, Lian CG. Molecular testing for cutaneous melanoma: an update and review. Arch Pathol Lab Med. 2019;143:811–820.
Soura E, Eliades PJ, Shannon K, et al. Hereditary melanoma: update on syndromes and management: genetics of familial atypical multiple mole melanoma syndrome. J Am Acad Dermatol. 2016;74:395–407; quiz 408–410.
Castiglione R, Ihle MA, Heydt C, et al. The impact of sequencing on diagnosis and treatment of malignant melanoma. Expert Rev Mol Diagn. 2016;16:423–433.
Colombino M, Capone M, Lissia A, et al. BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma. J Clin Oncol. 2012;30:2522–2529.
Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med. 2010;363:809–819.
Shain AH, Yeh I, Kovalyshyn I, et al. The genetic evolution of melanoma from precursor lesions. N Engl J Med. 2015;373:1926–1936.
Gastman BR, Gerami P, Kurley SJ, et al. Identification of patients at risk of metastasis using a prognostic 31-gene expression profile in subpopulations of melanoma patients with favorable outcomes by standard criteria. J Am Acad Dermatol. 2019;80:149–157.e144.
Gerami P, Cook RW, Russell MC, et al. Gene expression profiling for molecular staging of cutaneous melanoma in patients undergoing sentinel lymph node biopsy. J Am Acad Dermatol. 2015;72:780–785.e783.
Gerami P, Cook RW, Wilkinson J, et al. Development of a prognostic genetic signature to predict the metastatic risk associated with cutaneous melanoma. Clin Cancer Res. 2015;21:175–183.
Gerami P, Yao Z, Polsky D, et al. Development and validation of a noninvasive 2-gene molecular assay for cutaneous melanoma. J Am Acad Dermatol. 2017;76:114–120.e112.
Yeh I, de la Fouchardiere A, Pissaloux D, et al. Clinical, histopathologic, and genomic features of Spitz tumors with ALK fusions. Am J Surg Pathol. 2015;39:581–591.
Wiesner T, He J, Yelensky R, et al. Kinase fusions are frequent in Spitz tumours and Spitzoid melanomas. Nature Com. 2014;5:3116.
Quan VL, Panah E, Zhang B, et al. The role of gene fusions in melanocytic neoplasms. J Cutan Pathol. 2019;46:878–887.
Wiesner T, Kutzner H, Cerroni L, et al. Genomic aberrations in Spitzoid melanocytic tumours and their implications for diagnosis, prognosis and therapy. Pathology. 2016;48:113–131.
Quan VL, Zhang B, Zhang Y, et al. Integrating next-generation sequencing with morphology improves prognostic and biologic classification of Spitz neoplasms. J Invest Dermatol. 2020;140:1599–1608.
Gerami P, Cooper C, Bajaj S, et al. Outcomes of atypical Spitz tumors with chromosomal copy number aberrations and conventional melanomas in children. Am J Surg Pathol. 2013;37:1387–1394.
Harms KL, Lowe L, Fullen DR, et al. Atypical Spitz tumors: a diagnostic challenge. Arch Pathol Lab Med. 2015;139:1263–1270.
Harms PW, Hocker TL, Zhao L, et al. Loss of p16 expression and copy number changes of CDKN2A in a spectrum of Spitzoid melanocytic lesions. Hum Pathol. 2016;58:152–160.
Tetzlaff MT, Reuben A, Billings SD, et al. Toward a molecular-genetic classification of Spitzoid neoplasms. Clin Lab Med. 2017;37:431–448.
Lee S, Barnhill RL, Dummer R, et al. TERT promoter mutations are predictive of aggressive clinical behavior in patients with spitzoid melanocytic neoplasms. Sci Rep. 2015;5:11200.
Beaubier N, Tell R, Huether R, et al. Clinical validation of the Tempus xO assay. Oncotarget. 2018;9:25826–25832.
Halperin RF, Carpten JD, Manojlovic Z, et al. A method to reduce ancestry related germline false positives in tumor only somatic variant calling. BMC Medical Genomics. 2017;10:61.
Sun JX, He Y, Sanford E, et al. A computational approach to distinguish somatic vs. germline origin of genomic alterations from deep sequencing of cancer specimens without a matched normal. PLoS Comput Biol. 2018;14:e1005965.
Fleiss JL. Statistical Methods for Raters and Proportions, 3rd ed. New York, NY: Wiley; 2003.
Cohen J. A coefficient of agreement for nominal scales. Educ Psychol Meas. 1960;20:37–46.
Piepkorn M. On the nature of histologic observations: the case of the Spitz nevus. J Am Acad Dermatol. 1995;32(pt 1):248–254.
Piepkorn M. The Spitz nevus is melanoma. Am J Dermatopathol. 2005;27:367–369.
Barnhill RL, Argenyi ZB, From L, et al. Atypical Spitz nevi/tumors: lack of consensus for diagnosis, discrimination from melanoma, and prediction of outcome. Hum Pathol. 1999;30:513–520.
Elder D, Barnhill R, Bastian B, et al. Elder DE, Massi D, Scolyer RA, Willemze R. Melanocytic tumour classification and the pathway concept of melanoma pathogenesis. WHO Classification of Skin Tumours, 4th ed. Lyon, France: IARC; 2018:66–71.
Zhao G, Lee KC, Peacock S, et al. The utilization of Spitz-related nomenclature in the histological interpretation of cutaneous melanocytic lesions by practicing pathologists: results from the M-Path study. J Cutan Pathol. 2017;44:5–14.